TWM
VRTX icon

Tripletail Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tripletail Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Hold
290
– – 0.17% 100
2025
Q4 		$131K Sell
290
-20
-6% -$8.62K 0.17% 96
2025
Q3 		$126K Buy
+310
New +$130K 0.15% 104

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Tripletail Wealth Management's VRTX Position: Q1 2026 in Review

Tripletail Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 290 shares worth $127K. The position accounts for 0.17% of the portfolio, ranked #100.

Tripletail Wealth Management first reported a position in VRTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $131K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Tripletail Wealth Management held 290 shares of Vertex Pharmaceuticals worth $127K as of Q1 2026.
  • Tripletail Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.17% of Tripletail Wealth Management's portfolio in Q1 2026, its #100 holding.
  • Tripletail Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Tripletail Wealth Management's Vertex Pharmaceuticals position peaked at $131K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Tripletail Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.